Clinical trials
Phase 3 Leukemia, Lymphocytic, Chronic, B-Cell trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
51 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 2 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 7 |
| 2010 | 1 |
| 2012 | 4 |
| 2013 | 5 |
| 2014 | 5 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 3 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 3 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 25 |
| Active, not recruiting | 10 |
| Recruiting | 8 |
| Terminated | 7 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hoffmann-La Roche | 7 |
| Gilead Sciences | 5 |
| BeOne Medicines | 4 |
| Acerta Pharma BV | 3 |
| Janssen Research & Development, LLC | 3 |
| Loxo Oncology, Inc. | 3 |
| Pharmacyclics LLC. | 3 |
| AbbVie | 2 |
| Celgene | 2 |
| Merck Sharp & Dohme LLC | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Lymphocytic, Chronic, B-Cell | 51 |
| Lymphoma, Non-Hodgkin | 9 |
| Leukemia | 7 |
| Lymphoma | 7 |
| Lymphoma, Follicular | 7 |
| Burkitt Lymphoma | 6 |
| Lymphoma, B-Cell, Marginal Zone | 6 |
| Lymphoma, Large B-Cell, Diffuse | 6 |
| Lymphoma, Mantle-Cell | 6 |
| Multiple Myeloma | 6 |
Trials
Showing 1 to 25 of 51. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.